RecruitingNCT05196334

Pharmacotyping of Pancreatic Patient-derived Organoids

Pharmacotyping of Patient-derived Pancreatic Cancer Organoids From Endoscopic Ultrasound-guided Biopsy as a Tool for Predicting Oncological Response

Sponsor

Herlev Hospital

Enrollment

88 participants

Start Date

Jul 1, 2021

Study Type

OBSERVATIONAL

Conditions

Pancreatic Cancer

Summary

EUS-FNB samples will be used for organoid cultures, which will be co-cultured with cancer associated fibroblasts derived from the surrounding stroma of the lesion. The organoid cultures will be used for pharmacotyping using relevant chemotherapeutic agents used in the clinic, and the organoid's response compared with the patient's response.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether tiny lab-grown tumor models (called organoids, grown from a patient's own cancer cells) can predict how a person's pancreatic cancer will respond to different chemotherapy drugs — helping doctors choose the best treatment. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with locally advanced pancreatic cancer (not yet spread to distant organs) - You are about to start standard chemotherapy treatment - Your blood counts and organ function are within acceptable ranges - Your expected survival is more than 3 months **You may NOT be eligible if...** - Your pancreatic cancer has spread to distant organs (metastatic) - You have severe liver or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.